RU2018109979A - Способ получения бензоксазепиновых соединений - Google Patents

Способ получения бензоксазепиновых соединений Download PDF

Info

Publication number
RU2018109979A
RU2018109979A RU2018109979A RU2018109979A RU2018109979A RU 2018109979 A RU2018109979 A RU 2018109979A RU 2018109979 A RU2018109979 A RU 2018109979A RU 2018109979 A RU2018109979 A RU 2018109979A RU 2018109979 A RU2018109979 A RU 2018109979A
Authority
RU
Russia
Prior art keywords
reacting
reagent
iii
pph
paragraphs
Prior art date
Application number
RU2018109979A
Other languages
English (en)
Russian (ru)
Inventor
Реми АНЖЕЛО
Даниал Р. БОДРИ
Дайан Е. КАРРЕРА
Сушант МАЛХОТРА
Трэвис РЕМАРЧУК
Фредерик СТ-ЖАН
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2018109979A publication Critical patent/RU2018109979A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2018109979A 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений RU2018109979A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015138488A Division RU2649976C2 (ru) 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений

Publications (1)

Publication Number Publication Date
RU2018109979A true RU2018109979A (ru) 2019-02-28

Family

ID=50241450

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018109979A RU2018109979A (ru) 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений
RU2015138488A RU2649976C2 (ru) 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015138488A RU2649976C2 (ru) 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений

Country Status (15)

Country Link
US (1) US9303043B2 (enExample)
EP (3) EP2970329A1 (enExample)
JP (6) JP6363120B2 (enExample)
KR (3) KR20180070715A (enExample)
CN (2) CN105377856B (enExample)
AR (1) AR095365A1 (enExample)
AU (3) AU2014230812B2 (enExample)
BR (1) BR112015020716A2 (enExample)
CA (6) CA2897618A1 (enExample)
IL (1) IL240793A0 (enExample)
MX (1) MX2015011438A (enExample)
NZ (1) NZ711192A (enExample)
RU (2) RU2018109979A (enExample)
SG (2) SG10201706760YA (enExample)
WO (1) WO2014140073A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266903B2 (en) * 2013-12-16 2016-02-23 Genentech, Inc. Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
CN111909173B (zh) * 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
JP6522807B2 (ja) 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
EP3492452B1 (en) * 2016-07-29 2022-08-31 Japan Tobacco Inc. Production method for pyrazole-amide compound
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
ES2205944T3 (es) * 1998-10-23 2004-05-01 Dow Agrosciences Llc Compuestos de 3-(fenil sustituido)-5-(ciclopropil sustituido)-1,2,4-triazol.
HUP0400164A2 (hu) 2001-07-12 2004-07-28 Avecia Ltd. Mikrokapszulázott katalizátor, eljárás előállítására és alkalmazása
CA2463441A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
EA016527B1 (ru) * 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Триазолопиридазиновые модуляторы протеинкиназ
BRPI0717320A2 (pt) * 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
CA2675755C (en) * 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
WO2009055730A1 (en) * 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
CN102015693B (zh) * 2008-02-21 2014-10-29 默沙东公司 作为erk抑制剂的化合物
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
TWI423980B (zh) * 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯pi3k抑制劑化合物及使用方法
CA2778684A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
KR20140032383A (ko) 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合

Also Published As

Publication number Publication date
JP2016512209A (ja) 2016-04-25
AU2014230812A1 (en) 2015-09-03
CA2948763A1 (en) 2014-09-18
JP2020114814A (ja) 2020-07-30
CN105377856B (zh) 2018-05-22
RU2015138488A (ru) 2017-04-20
CA2948765A1 (en) 2014-09-18
JP2019089762A (ja) 2019-06-13
SG10201706760YA (en) 2017-10-30
CN108929333A (zh) 2018-12-04
EP3404032A2 (en) 2018-11-21
AR095365A1 (es) 2015-10-14
AU2014230812B2 (en) 2016-04-07
CA3005118A1 (en) 2014-09-18
CA2948763C (en) 2018-04-24
WO2014140073A1 (en) 2014-09-18
CA2897618A1 (en) 2014-09-18
EP3404032A3 (en) 2019-03-13
KR20170070270A (ko) 2017-06-21
CA3005112A1 (en) 2014-09-18
AU2014230812A8 (en) 2015-09-10
EP3404032C0 (en) 2025-07-02
NZ711192A (en) 2019-04-26
KR20180070715A (ko) 2018-06-26
EP3845540B1 (en) 2026-07-22
JP6442005B2 (ja) 2018-12-19
CA3005103A1 (en) 2014-09-18
US20140275523A1 (en) 2014-09-18
JP2018008959A (ja) 2018-01-18
AU2018201393A1 (en) 2018-03-15
EP2970329A1 (en) 2016-01-20
US9303043B2 (en) 2016-04-05
KR101871133B1 (ko) 2018-06-25
HK1215433A1 (zh) 2016-08-26
MX2015011438A (es) 2016-02-03
RU2649976C2 (ru) 2018-04-06
JP2019031493A (ja) 2019-02-28
EP3845540A1 (en) 2021-07-07
AU2016204432B2 (en) 2017-12-07
IL240793A0 (en) 2015-10-29
JP2018150298A (ja) 2018-09-27
JP6363120B2 (ja) 2018-07-25
AU2016204432A1 (en) 2016-07-21
KR101821468B1 (ko) 2018-01-23
CN105377856A (zh) 2016-03-02
JP6663459B2 (ja) 2020-03-11
EP3404032B1 (en) 2025-07-02
BR112015020716A2 (pt) 2017-07-18
KR20150119033A (ko) 2015-10-23
SG11201507394RA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
RU2015138488A (ru) Способ получения бензоксазепиновых соединений
JP2018008959A5 (enExample)
DK3106463T6 (da) Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
CL2007003671A1 (es) Metodo para la preparacion de derivados del acido 2-amino-5-cianobenzoico, utiles como intermediarios para la preparacion de las correspondientes diamidas cianoantranilicas.
ZA201101039B (en) Highly porous foam ceramics as catalyst carriers for the dehydrogenation of alkanes
RU2005136234A (ru) Катализатор синтеза этиленоксида
Ito et al. Discovery of spiro [indole-3, 2′-pyrrolidin]-2 (1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP
RU2015113747A (ru) Способ получения соединений тиенопиримидина
WO2013183035A3 (en) Amides of 2-amino-4-arylthiazole compounds and their salts
CL2008001131A1 (es) Solucion de manoproteinas; proceso para producir dicha solucion de manoproteinas; proceso para estabilizar vino impidiendo o retardando la cristalizacion de sales de acido tartarico.
FR2873372B1 (fr) Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
CN106905350B (zh) 一种噻唑并[3,2-α]吡啶衍生物的制备方法及其制备用催化剂
MX373379B (es) Catalizador y proceso para oxicloración de etileno en dicloroetano.
IT1396210B1 (it) Metodo di realizzazione di un dispositivo di rigenerazione di tessuti biologici, particolarmente per la rigenerazione di tessuti appartenenti al sistema nervoso periferico.
EA201291289A1 (ru) Кристаллическое производное тиенопиримидина
CN103613597A (zh) 一种枸橼酸爱地那非的制备工艺
CN104844598A (zh) 8-甲氧基甲酸乙酯咪唑并[1,2a]吡啶-3-甲酸乙酯的合成方法
DK1646582T3 (da) Fremgangsmåde til fremstilling af aluminumtrihydrater med höjt porevolumen
NO20055153D0 (no) Fremgangsmate for fremstilling av maursyreformiater
ES1058046Y (es) Vestidor para bebes con sistema de pesaje
RU2013136948A (ru) Способ получения 5(6)-амино-2-(4-аминофенил)бензимидазола
RU2007105420A (ru) Способ очистки крови от днк-содержащих иммунных комплексов с помощью иммобилизированного гранулированного магнитоуправляемого препарата
RU2009137831A (ru) Способ получения катализатора винилацетата
RU2015145487A (ru) Способ получения эрлотиниба
Shelud'ko et al. MORFOLOGIChESKAYa ADAPTATsIYa ORGANOV I TKANEY PRI ZhENSKOM ALKOGOLIZME

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20170313